Pharmacology

Antithrombotic Anticoagulants

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Original title: Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug...

solaci - 24 June, 2014

Learn More

Antiplatelet

Increased security with bivalirudin than with heparin alone in patients without ST segment.

Original title: Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes...

solaci - 14 May, 2014

Learn More

Acute coronary syndromes

Higher event rate in those with non-ST elevation ACS who received revascularization at PLATO study. Beyond this, ticagrelor reduced mortality.

Original title: Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from...

solaci - 7 May, 2014

Learn More

Antithrombotic Anticoagulants

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months...

solaci - 25 February, 2014

Learn More

Acute coronary syndromes

Almost 40 % of those who initially receive clopidogrel then switch to prasugrel or ticagrelor in clinical practice.

Original title: In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary...

solaci - 7 February, 2014

Learn More

Acute coronary syndromes

Decreased bleeding with radial access leaves little to bivalirudin for additional benefit

Original title: Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry. Reference: Sciahbasi...

solaci - 31 January, 2014

Learn More

Antithrombotic Anticoagulants

Stent reestenosis, the only subgroup that benefits from longer double antiaggregation

Original title: Short vs. Long Term Duration of Dual Antiplatelet Therapy in Patients treated for InstentRestenosis. A PRODIGY...

solaci - 13 December, 2013

Learn More

Antithrombotic Anticoagulants

Clopidogrel suspension, without rebound in stable patients

Original title: A randomised controlled trial of platelet activity before and after cessation of clopidogrel therapy in...

solaci - 20 November, 2013

Learn More

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Increased security with bivalirudin than with heparin alone in patients without ST segment.

Higher event rate in those with non-ST elevation ACS who received revascularization at PLATO study. Beyond this, ticagrelor reduced mortality.

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Almost 40 % of those who initially receive clopidogrel then switch to prasugrel or ticagrelor in clinical practice.

Decreased bleeding with radial access leaves little to bivalirudin for additional benefit

Stent reestenosis, the only subgroup that benefits from longer double antiaggregation

Clopidogrel suspension, without rebound in stable patients

Last News

Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Institutional News

SOLACI Wishes You Happy Holidays

Condolences on the passing of Cristiam Arancibia

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Access